Keyword: Lonza


Lonza Announces New Mid-Term Guidance 2024 – 2028

17.10.2023 -

At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Chemistry & Life Sciences

Spray Drying for Inhalation: the Challenges of Scale-up

16.10.2023 -

When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key...


Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

06.10.2023 -

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner...

Research / Laboratory

Successful Clinical to Commercial Bioconjugate Manufacturing

Lonza AG -

Ever since antibody drug conjugates (ADCs) were first reported in the 1970s, the field of bioconjugation has found itself in a constant state of evolution.


Lonza-CEO Ruffieux to Leave Swiss CDMO

18.09.2023 -

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September.

Markets & Companies

The Evolution of CDMOs

13.09.2023 -

Contract development and manufacturing organizations (CDMOs) are a crucial part of the life sciences industry. Strangely, despite its current prominence, the CDMO...


Lonza, Vertex Break Ground on New US Cell Therapy Plant

05.09.2023 -

Last week, Lonza and Vertex Pharmaceuticals broke ground on a new US facility in Portsmouth, New Hampshire, to manufacture cell therapies for diabetes.

Research / Laboratory

Improving ADC Production and Purification

Lonza AG -

How Optimizing Process Parameters Can Improve Scalability and Manufacturability of a Cytotoxic Antibody Drug Conjugate.